Table 2. Summary of Adverse Events .
| Event | Treatment group, No. (%) | ||
|---|---|---|---|
| Placebo (n = 78) | Abrocitinib | ||
| 100 mg (n = 158) | 200 mg (n = 155) | ||
| Deaths | 0 | 1 (0.6) | 0 |
| Serious adverse events of any cause | 1 (1.3) | 5 (3.2) | 2 (1.3) |
| Most frequently reported TEAEs of any cause (≥3% in any treatment group) | |||
| Nausea | 2 (2.6) | 12 (7.6) | 22 (14.2) |
| Nasopharyngitis | 5 (6.4) | 20 (12.7) | 12 (7.7) |
| Headache | 2 (2.6) | 9 (5.7) | 12 (7.7) |
| Upper respiratory tract infection | 3 (3.8) | 14 (8.9) | 5 (3.2) |
| Dermatitis atopic | 12 (15.4) | 9 (5.7) | 6 (3.9) |
| Acne | 0 | 2 (1.3) | 9 (5.8) |
| Vomiting | 1 (1.3) | 2 (1.3) | 8 (5.2) |
| Upper abdominal pain | 0 | 2 (1.3) | 6 (3.9) |
| Blood creatine phosphokinase increased | 2 (2.6) | 3 (1.9) | 5 (3.2) |
| Folliculitis | 2 (2.6) | 0 | 5 (3.2) |
| Thrombocytopenia | 0 | 0 | 5 (3.2) |
Abbreviation: TEAE, treatment-emergent adverse event.